How to Interpret an Investigator’s Brochure for Meaningful Risk Assessment: Results of an AGAH Discussion Forum (2024)

Table 1.

Table of Contents of the IB as Exemplified in ICH E6 (R2) [1].

Translational Integration of Non-clinical Data from the Investigator’s Brochure

The keynote lecture addressed better ways for displaying and interpreting data within IBs and focused on the recent development of a tool that can be used to integrate and display specific data [6]. The tool consists of a database in which relevant results from non-clinical studies on the IMP are entered. The tool enables data to be sorted in tabulated rows by increasing maximum systemic drug concentrations (C_max) or by increasing estimated human equivalent doses. Missing data on C_max may need to be interpolated from population pharmaco*kinetic models or from other studies within the same species. Results from pharmacology, safety, and toxicology studies can be differentiated by colour (e.g. blank = no data, green = pharmacologically or therapeutically desirable, yellow-orange = increasingly severe reversible adverse events, red = irreversible toxicity and death). Adding an anticipated human effective maximum concentration or dose or even data from first clinical trials allows the sponsor and the investigator to get an overview on all non-clinical data for the IMP and to obtain an overview of whether the intended human doses are expected to be safe for administration in humans. Several real-world examples illustrated the practicability of the tool which is freely available for use (www.ib-derisk.org) [6].

The emphasis of this approach is on acute, potentially adversely exaggerated pharmacological effects correlating with C_max. Dose-limiting acute adverse responses to substances of certain classes, such as compounds causing pharmacologically mediated functional central nervous system (CNS) effects, may directly correlate with maximal systemic plasma/serum concentrations and are a typical function of the pharmacological on-target activity [7]. However, for most drug classes, including CNS-active drugs, the full characterisation of the safety profile requires repeated dosing and exposure data in terms of area under the concentration–time curve (AUC) which are often more predictive of how effects will translate from one species to another, with the exception of acute functional effects [8].

Deficiencies/Uncertainties in IBs: Quality of IB Sections 1 to 6

The German Medicinal Products Act requires that ‘each investigator has been informed by a scientist responsible for the pharmacological-toxicological test about the findings of the test and the foreseeable risks involved in the clinical trial’ [9]. Although this information is provided in the IB, this prerequisite to conducting clinical trials with the IMP has the inherent implication that an identifiable scientist takes responsibility for the acceptability of the risk to subjects by providing the signed approval in the IB. Deficiencies observed by the BfArM refer to the use of different IB versions in parallel and to IB changes considered as non-substantial by the sponsor although they had to be regarded as substantial according to the assessment by BfArM.

The availability of new non-clinical and/or clinical data is usually considered substantial as they could have an impact on safety of subjects in clinical trials and need to be scientifically reviewed by the national competent authority, whereas non-substantial amendments are processed administratively only. The sponsor must assess any new information to evaluate its potential impact on the established risk/benefit profile. The BfArM requires the sponsor to provide this assessment for the IMP and the ongoing trials, justifying why either the risk/benefit assessment remains unchanged or why existing measures are considered adequate to control for any newly identified risks or previously established risks with an altered appraisal (e.g. lower NOAEL with prolonged treatment but same principal target organ).

It was general consensus that similar to clinical trial protocols, the IB should include a last section on the amendment change history. Overall, it is the task of the sponsor to constantly evaluate the risk/benefit of an ongoing clinical trial, and the competent authority must be able to scrutinise this assessment objectively.

The findings of the online survey asking participants about the overall content quality of the IB they have previously used for early development clinical trials revealed a mean score of 3.6 (where a score of 1 = very bad and 5 = very good). The majority of participants (55%) gave a rating of 4. More detailed participant questioning revealed mean scores of 3.1 for readability, 3.3 for comprehensibility, 3.3 for appropriateness for risk assessment, 3.6 for timeliness, 3.3 for quality of presented non-clinical information, and 3.7 for quality of presented clinical information.

Guidance for the Investigator: Quality of IB Section7

Important requirements for this section of the IB from the viewpoint of the investigator are completeness and correctness of data as well as clarity, comprehensibility, and relevance of the information provided [10]. It is generally agreed that this is best achieved through the logical presentation of data, indication of important missing data, and comprehensive conclusions containing guidance for dosing, warning messages on adverse reaction that might be expected with the IMP, and recommendations on appropriate measures to deal with IMP-related medical emergencies.

From the point of view of the ethics committee, non-clinical studies on pharmacology should include elements essential for ensuring validity such as randomisation, sample size calculation, and blinded outcome assessments [11]. Non-clinical pharmacology studies to establish the proof-of-principle for a given investigational medicinal product (IMP) are ideally undertaken in various disease models since many of them face limitations regarding their predictive value for the human condition, and a combination of studies provides a more meaningful basis to assess the relevance of the data. Typically, some studies may not show evidence of efficacy whereas others are positive. However, all pharmacology studies including those with negative outcomes should be reported in order to avoid assessment bias and to allow investigators to appraise the strength of the supporting preclinical data systematically which should be reflected in the guidance for the investigator [11].

Reference Safety Information in the IB

According to the ‘detailed guidance on the collection, verification and presentation of adverse event/reaction reports arising from clinical trials on medicinal products for human use’ issued by the European Commission [12] and according to ‘regulation (EU) no 536/2014 of the European Parliament and of the Council on clinical trials on medicinal products for human use’ [13], the IB shall include a clearly identifiable section called the ‘Reference Safety Information’ (RSI). The RSI shall contain information on the IMP, how to determine whether adverse reactions should be considered as expected adverse reactions, and on the expected frequency and nature of such adverse reactions [13]. The sponsor’s informed opinion on the expectedness of an adverse reaction must be provided from the perspective of previously observed events rather than the basis of what might be anticipated from the pharmacological properties of the IMP [12].

More specific guidance was recently issued in the form of a Questions & Answers publication by the Clinical Trial Facilitation Group (CTFG) [14]. It was highlighted how the RSI should be used by the sponsor for the assessment of the expectedness of all suspected serious adverse reactions (SARs) occurring in clinical trials in order to assess the need for expedited safety reporting [15]. It was determined that the content of the RSI should include a clear list of ‘expected SARs’, i.e. SARs that could be expected following exposure to the IMP. The list should be restricted to ‘suspected’ SARs that had previously been observed and where, after a thorough assessment by the sponsor, reasonable evidence of a causal relationship between the event and the IMP had been established [14]. By implication, each ‘expected SAR’ should already have been reported as a ‘suspected’ SAR more than once. Where SARs turned out to be fatal and life-threatening, they would usually be considered to be unexpected even if the fatal or life-threatening SARs had been reported previously [14]. In the IB, the sponsor should clearly indicate that the RSI section outlines expected SARs for regulatory reporting purposes and that the information in the RSI section does not present a comprehensive overview of the safety profile of the IMP. Therefore, the RSI should always be provided in a clearly separated and specific section of the IB [13].

It is required that the RSI be presented in a table form where the ‘expected SARs’ are listed by body system organ class using preferred terms as per the latest MedDRA version followed by frequency of incidence calculated on an aggregated level based on previously observed ‘suspected’ SARs. Where necessary, the RSI section of the IB is to be updated annually after the Development Safety Update Report data-lock point by a substantial amendment. All other safety information comprising a detailed overview on the safety profile of the IMP should be provided in the subsection on the ‘Effects in Humans’ and in the ‘Summary of Data and Guidance to the Investigator’ (Section7) [14, 16].

Following discussion over the RSI, participants indicated through the online survey that most (63%) were familiar with the CTFG Q&A document and that they were used to seeing this information provided as a separate section in some, though not all, of the IBs they had worked with. When debating their involvement in the production of IBs, the majority of participants (61%) indicated that they preferred to locate the RSI as a separate section, Section8, rather than as a subsection of Section7. These results are in line with data from a previous web-based survey that was conducted to understand current industry practices in the preparation of safety information for the IB [16].

Potential Risks for Human Subjects Associated with Inadequate Non-clinical Safety Assessment

The ICH E6 (R2) guideline for Good Clinical Practice requires that results of all relevant non-clinical pharmacology, toxicology, pharmaco*kinetic, and metabolism studies be provided in a summary form within the IB addressing the methodology and discussing the relevance of the findings to the IMP and the possible unfavourable and unintended effects in humans [1]. It is emphasised that where possible, data should be provided in tabular form to enhance the clarity of its presentation. It was generally agreed that provision of these data in a format that is difficult to interpret would be associated with unwarranted risk in terms of the overall conduct of the clinical trial assuming that critical information could be missed. One example where inadequate presentation might introduce risk would be investigations that had been performed but werenot discussed or presented in the IB or cases where the sponsor provides insufficient discussion regarding the relevance of pharmacodynamic models, species differences, off-target effects, safety margins, or findings from non-clinical safety studies. It may also include listing of results in the absence of context and/or a lack of expert interpretation.

Key objectives of the non-clinical safety programme are to identify:

1. the initial safe starting dose and subsequent dose escalation schemes in humans;

2. potential target organ systems for toxicity including dose dependence of adverse effects, any relation to exposure over the dose range tested (C_max and AUC in each species tested including total and free drug including predicted safety margins compared to predicted efficacious exposures in humans), and the assessment of reversibility of adverse effects;

3. safety parameters for clinical monitoring [5, 17].

It is the purpose of the IB to describe all these characteristics of the IMP clearly. In particular for early IBs, the results obtained from the non-clinical safety package need to be addressed in appropriate detail and context in order to support the development of a benefit-risk assessment based on the totality of the available evidence. The interpretation of critical findings such as mortality in toxicology studies should be robust and interrogated to establish whether there is any underlying cause for concern, whether it is possible to establish such an opinion with the data available and if so, based on which observations. Key considerations include but are not limited to the nature, type, and severity of the findings across species and studies, their relation to exposures over the dose range tested, the steepness of the dose–response, and predicted safety margins [8]. If any important issues are identified during non-clinical development, it is mandatory to assess critically whether they require clinical development to be put on hold and whether any risks can be mitigated and/or explained. While findings may be deemed to have a negative impact on the risk/benefit profile but the safety of subjects in clinical trials can still be ensured with the overall risk/benefit profile remaining positive, initial measures intended to mitigate potential risks may need to be modified. Any new measures introduced to mitigate risk and address any management needs must be explained clearly and justified. All relevant data should be presented in a transparent manner to convey salient information supporting human risk assessment clearly and concisely.

In debating the production of IBs, it was agreed by the participants that they represent a living document critical to the clinical development of new medicines that are constantly changing as we learn more about an IMP. As such, this places emphasis on producing documents containing the correct information and therefore should be given sufficient time and resources to produce and maintain quality documents, keeping them appropriately updated with new information from all disciplines [10]. Ongoing and interdisciplinary risk assessments must be undertaken regularly and at appropriate junctures to integrate all data, and to identify and address any emerging concerns in a timely manner.

Possible Improvements to the IB

The final session of the discussion forum involved a group debate on whether it was possible for any parts of the IB to be improved and if so, how that could be delivered. The overall opinion of the participants is summarised in Table ​Table2.2. The IB section that most of the participants perceived in need for improvement was the summary of data and guidance for the investigator (Section7), followed by the non-clinical studies (Section5) and the effects in humans (Section6). It was generally perceived that this represented a call to the sponsors of clinical trials and the authors of the IBs to diligently optimise the data presentation in order to ensure the best possible understanding of the IMP characteristics by the investigator and permit an optimal benefit-risk assessment which safeguards those taking part in clinical trials.

Conflict of interest

The authors declare the following conflicts of interest: Jens Rengelshausen: The author is an employee of Grünenthal GmbH. Frank Donath: The author is an employee of SocraTec Research and Development GmbH. Tim Hardman: The author is an employee of Niche Science & Technology Ltd., UK. Georg Wensing: The author is an employee of Bayer AG. Kerstin Breithaupt-Groegler, Katharina Erb-Zohar, Gerd Mikus, Stephanie Plassmann and Hildegard Sourgens state that they have no conflict of interest to declare. The views and opinions expressed in this publication document the course of the discussion forum and do not necessarily reflect those of the authors’ affiliations.

2. Ponzano S, Blake K, Bonelli M, Enzmann H, on behalf of the European Medicines Agency Committee for Human Medicinal Products “First-in-Human Guideline Drafting Group Promoting safe early clinical research of novel drug candidates: a European Union regulatory perspective. Clin Pharmacol Ther. 2018;103:564–566. doi:10.1002/cpt.899. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

3. Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, Brunner MD, et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med. 2006;355:1018–1028. doi:10.1056/NEJMoa063842. [PubMed] [CrossRef] [Google Scholar]

4. Kerbrat A, Ferré JC, Fillatre P, Ronzière T, Vannier S, Carsin-Nicol B, et al. Acute neurologic disorder from an inhibitor of fatty acid amide hydrolase. N Engl J Med. 2016;375:1717–1725. doi:10.1056/NEJMoa1604221. [PubMed] [CrossRef] [Google Scholar]

6. van Gerven J, Cohen A. Integrating data from the Investigational Medicinal Product Dossier/investigator's brochure. A new tool for translational integration of preclinical effects. Br J Clin Pharmacol. 2018;84:1457–1466. doi:10.1111/bcp.13529. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

7. Ettlin RA, Kuroda J, Plassmann S, Prentice DE. Successful drug development despite adverse preclinical findings. Part 1: processes to address issues and most important findings. J Toxicol Pathol. 2010;23:189–211. doi:10.1293/tox.23.189. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

8. Koch E, Plassmann S. Critical aspects of integrated preclinical drug development: concepts, strategies and potential pitfalls. In: Faqi AS, editor. A comprehensive guide to toxicology in preclinical drug development. 2. Cambridge: Academic Press; 2017. [Google Scholar]

10. Fiebig D. The Investigator’s Brochure: a multidisciplinary document. Med Writing. 2014;23:96–100. doi:10.1179/2047480614Z.000000000212. [CrossRef] [Google Scholar]

11. Wieschowski S, Chin WWL, Federico C, Sievers S, Kimmelman J, Strech D. Preclinical efficacy studies in investigator brochures: do they enable risk-benefit assessment? PLoS Biol. 2018;16:e2004879. doi:10.1371/journal.pbio.2004879. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

12. European Commission. Communication from the Commission—Detailed guidance on the collection, verification and presentation of adverse event/reaction reports arising from clinical trials on medicinal products for human use (‘CT-3’). Official Journal of the European Union 2011/C 172/01.

13. Regulation (EU) No 536/2014 of the European Parliament and of the Council of 16 April 2014 on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC. Official Journal of the European Union 2014/ L 158/1.

15. Sherman RB, Woodco*ck J, Norden J, Grandinetti C, Temple RJ. New FDA regulation to improve safety reporting in clinical trials. N Engl J Med. 2011;365:3–5. doi:10.1056/NEJMp1103464. [PubMed] [CrossRef] [Google Scholar]

16. Klepper MJ, Fontaine L. Survey of safety information in the investigator’s brochure: inconsistencies and recommendations. Ther Innov Regul Sci. 2018;52:764–770. doi:10.1177/2168479018768514. [PubMed] [CrossRef] [Google Scholar]